Amifostine for Head and Neck Cancer Patients
American Society for Radiation Oncology (ASTRO)A new drug is proving to be effective in treating one of the most common side effects patients suffer during and after radiation treatments for head and neck cancer. The drug, amifostine, is easing xerostomia (severe dry mouth), a condition that can make it very difficult for these patients to eat, drink and even speak. The study was presented at the American Society for Therapeutic Radiology annual meeting October 31 - November 4, 1999 in San Antonio, TX.